127 related articles for article (PubMed ID: 8948048)
1. The effect of heparin and its neutralisation on functional assays for factor VIIa, factor VII and TFPI.
Cardigan RA; Mackie IJ; Machin SJ
Thromb Res; 1996 Nov; 84(4):237-42. PubMed ID: 8948048
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of heparin and tissue factor pathway inhibitor on factor VII assays. possible implications for measurements in vivo after heparin therapy.
Bladbjerg EM; Larsen LF; Ostergaard P; Jespersen J
Blood Coagul Fibrinolysis; 2000 Dec; 11(8):739-45. PubMed ID: 11132652
[TBL] [Abstract][Full Text] [Related]
3. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
[TBL] [Abstract][Full Text] [Related]
4. Seminal factor VII and factor VIIa: supporting evidence for the presence of an active tissue factor-dependent coagulation pathway in human semen.
Lwaleed BA; Goyal A; Delves G; Gossai S; Greenfield RS; Cooper AJ
Int J Androl; 2007 Dec; 30(6):543-9. PubMed ID: 17459125
[TBL] [Abstract][Full Text] [Related]
5. Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin.
Hansen JB; Svensson B; Sandset PM; Thijssen F
Thromb Res; 2000 Dec; 100(5):389-96. PubMed ID: 11150580
[TBL] [Abstract][Full Text] [Related]
6. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
[TBL] [Abstract][Full Text] [Related]
7. Factor VII and activated-factor-VII content of prothrombin complex concentrates. The PCC Study Group.
Hellstern P; Beeck H; Fellhauer A; Fischer A; Faller-Stöckl B
Vox Sang; 1997; 73(3):155-61. PubMed ID: 9358617
[TBL] [Abstract][Full Text] [Related]
8. Measurement of factor VII and of activated factor VII in healthy individuals and in prothrombin complex concentrates.
Hellstern P; Beeck H; Fellhauer A; Fischer A; Faller-Stöckl B
Thromb Res; 1997 Jun; 86(6):493-504. PubMed ID: 9219329
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
Harenberg J; Malsch R; Angelescu M; Lange C; Michaelis HC; Wolf H; Heene DL
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):477-83. PubMed ID: 8840001
[TBL] [Abstract][Full Text] [Related]
10. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor.
Hamamoto T; Kisiel W
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):470-6. PubMed ID: 8840000
[TBL] [Abstract][Full Text] [Related]
11. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.
Morrissey JH; Macik BG; Neuenschwander PF; Comp PC
Blood; 1993 Feb; 81(3):734-44. PubMed ID: 8427965
[TBL] [Abstract][Full Text] [Related]
12. The strong positive correlation between factor VII clotting activity using bovine thromboplastin and the activated factor VII level.
Kario K; Matsuo T; Asada R; Sakata T; Kato H; Miyata T
Thromb Haemost; 1995 Mar; 73(3):429-34. PubMed ID: 7667824
[TBL] [Abstract][Full Text] [Related]
13. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
[TBL] [Abstract][Full Text] [Related]
14. Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin.
Kristensen HI; Ostergaard PB; Nordfang O; Abildgaard U; Lindahl AK
Thromb Haemost; 1992 Sep; 68(3):310-4. PubMed ID: 1332210
[TBL] [Abstract][Full Text] [Related]
15. [Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction].
Xiong SL; Wang Q; Zheng L; Li JL; Wen ZB; He SL
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1821-3. PubMed ID: 18158992
[TBL] [Abstract][Full Text] [Related]
16. Heparin blunts endotoxin-induced coagulation activation.
Pernerstorfer T; Hollenstein U; Hansen J; Knechtelsdorfer M; Stohlawetz P; Graninger W; Eichler HG; Speiser W; Jilma B
Circulation; 1999 Dec 21-28; 100(25):2485-90. PubMed ID: 10604885
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
[TBL] [Abstract][Full Text] [Related]
18. Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations.
Jeske W; Hoppensteadt D; Fareed J; Bermes E
Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S73-80. PubMed ID: 7647226
[TBL] [Abstract][Full Text] [Related]
19. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI.
Lindahl AK; Abildgaard U; Larsen ML; Staalesen R; Hammer AK; Sandset PM; Nordfang O; Beck TC
Thromb Res; 1991 Jun; 62(6):607-14. PubMed ID: 1926055
[TBL] [Abstract][Full Text] [Related]
20. Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII.
Goudemand J; Caron C; Dreyfus M; Sié P;
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):505-11. PubMed ID: 12851539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
